Design of a new psychedelic quipazine analog with therapeutic efficacy and potentially fewer side effects.
Abstract
Psychedelics that target serotonin 2A receptors (5-HT<sub>2A</sub>Rs) hold therapeutic promise for neuropsychiatric disorders but are often hindered by off-target actions. The 5-HT<sub>2A</sub>R agonist quipazine also activates 5-HT<sub>3</sub>R, which contributes to undesirable side effects. Here, we developed VCU-1012, a quipazine-based, structurally distinct 5-HT<sub>2A</sub>R agonist devoid of 5-HT<sub>3</sub>R activity. VCU-1012 was developed by applying a strategic chemical design that combined deconstruction to pinpoint the nitrogen atom critical for 5-HT<sub>2A</sub>R activation with structure-activity relationship studies to minimize 5-HT<sub>3</sub>R agonism. We showed that VCU-1012 modulated dendritic spine structural plasticity in the frontal cortex and produced antidepressant-like effects in mice through 5-HT<sub>2A</sub>R without activating 5-HT<sub>3</sub>R, thereby avoiding the gastrointestinal side effects of quipazine. In addition, our molecular modeling and mutant analysis suggested that VCU-1012 interacted in the canonical orthosteric binding pocket of 5-HT<sub>2A</sub>R. Together, these findings establish VCU-1012 as a potential therapeutic agent with reduced gastrointestinal impact, emphasize how differences in ligand-receptor interactions influence ligand positioning in the receptor binding pocket, and provide guidance for designing psychedelics with targeted therapeutic benefits.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.